BioSpace

Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy

Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic

Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market

Eli Lilly CFO On Acquisition Spree: 'We Are Taking Bets' On Future Revenue

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail

A precision T-cell therapy stalls treatment-resistant cancers in clinical trial

Patient dies in Bristol Myers Squibb autoimmune CAR-T trial

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Structural basis for protocadherin-1 recognition by New World hantaviruses

‘Everything’s coming to fruition’: Renowned MGB neuroscientist to receive millions to combat Alzheimer’s

Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds

Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race

BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence

BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth

Major Parkinson’s breakthrough as new pill offers hope of treating symptoms and has fewer side-effects

Experimental vaccine shows promise against deadly brain cancer in some patients

Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down

Genentech pays Alector $100M for preclinical Parkinson’s prospect

Introducing Fierce Biotech's 2026 Fierce 15

Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal

Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D

Gay men share their journeys with prostate cancer & explain why early detection is everything

Merck licenses a KRAS G12D inhibitor for $400M upfront

Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal

New Parkinson’s drug approved in the US: What does it do differently?

Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags

Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century

Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details

Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.

Wegovy maker Novo shares slump as management grilled on pricing, M&A

Testosterone scripts for women rise, along with denials and delays

Novartis’ TREM2 drug fails Phase 2 ALS trial

Psychedelics Stock, Up 190% This Year, Flies High Again

Experts urge FDA to set clear safety and access standards for psychedelic drugs

No more Nordisk as Novo goes it alone amid rebranding push

Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

A ‘Transformative’ Narcolepsy Drug Opens New Opportunities in Neuroscience

Novartis Stock Tanks Following Third Major Pipeline Setback

Summit Packs A Punch For Merck's Keytruda

Newly approved pancreatic cancer drug shows promise in lung cancer

Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Alnylam’s heart drug troubles take center stage at a cardiology conference

Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial

The Race to Develop More Medicines Like the New Pancreatic Cancer Drug

Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal

RFK Jr. may upend how vaccine recommendations are categorized

Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.

For Narcoleptics, a 'New Chapter'

A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

The Surprising Reason This Biotech Plummeted 69%

EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.